CYTOKINETICS, INCORPORATED Operating Lease, Expense
CYTOKINETICS, INCORPORATED (CYTK) reported Operating Lease, Expense of $5.40 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2021-11-05
- CYTOKINETICS, INCORPORATED operating lease, expense for the quarter ending 2021-09-30 was $5.40M, a 285.71% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating lease, expense for the quarter ending 2021-06-30 was $5.30M, a 278.57% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating lease, expense for the quarter ending 2021-03-31 was $1.50M, a 7.14% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating lease, expense for the quarter ending 2020-12-31 was $1.50M, a 15.38% increase year-over-year.
- CYTOKINETICS, INCORPORATED operating lease, expense for fiscal 2020 was $5.70M, a 11.76% increase from fiscal 2019.
- CYTOKINETICS, INCORPORATED operating lease, expense for fiscal 2019 was $5.10M, a 2.00% increase from fiscal 2018.
- CYTOKINETICS, INCORPORATED operating lease, expense for fiscal 2018 was $5.00M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2021-09-30 | $5.40M 10-Q · filed 2021-11-05 | $10.70M derived: sum of 2 quarters · filed 2021-11-05 | $12.20M 10-Q · filed 2021-11-05 | $13.70M derived: sum of 4 quarters · filed 2021-11-05 |
| 2021-06-30 | $5.30M 10-Q · filed 2021-08-06 | $6.70M 10-Q · filed 2021-08-06 | $8.30M derived: sum of 3 quarters · filed 2021-08-06 | $9.70M derived: sum of 4 quarters · filed 2021-11-05 |
| 2021-03-31 | $1.50M 10-Q · filed 2021-05-07 | $3.00M derived: sum of 2 quarters · filed 2021-05-07 | $4.40M derived: sum of 3 quarters · filed 2021-11-05 | $5.80M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.90M derived: sum of 2 quarters · filed 2021-11-05 | $4.30M derived: sum of 3 quarters · filed 2021-11-05 | $5.70M 10-K · filed 2021-02-26 |
| 2020-09-30 | $1.40M 10-Q · filed 2021-11-05 | $2.80M derived: sum of 2 quarters · filed 2021-11-05 | $4.20M 10-Q · filed 2021-11-05 | $5.50M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $1.40M 10-Q · filed 2021-08-06 | $2.80M 10-Q · filed 2021-08-06 | $4.10M derived: sum of 3 quarters · filed 2021-08-06 | $5.40M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $1.40M 10-Q · filed 2021-05-07 | $2.70M derived: sum of 2 quarters · filed 2021-05-07 | $4.00M derived: sum of 3 quarters · filed 2021-05-07 | $5.30M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.60M derived: sum of 2 quarters · filed 2021-02-26 | $3.90M derived: sum of 3 quarters · filed 2021-02-26 | $5.10M 10-K · filed 2021-02-26 |
| 2019-09-30 | $1.30M 10-Q · filed 2020-11-06 | $2.60M derived: sum of 2 quarters · filed 2020-11-06 | $3.80M 10-Q · filed 2020-11-06 | $5.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $1.30M 10-Q · filed 2020-08-07 | $2.50M 10-Q · filed 2020-08-07 | $3.80M derived: sum of 3 quarters · filed 2021-02-26 | $5.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $1.30M 10-Q · filed 2020-05-08 | $2.50M derived: sum of 2 quarters · filed 2021-02-26 | $3.80M derived: sum of 3 quarters · filed 2021-02-26 | $5.10M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.50M derived: sum of 2 quarters · filed 2021-02-26 | $3.80M derived: sum of 3 quarters · filed 2021-02-26 | $5.00M 10-K · filed 2021-02-26 |
| 2018-09-30 | $1.30M 10-Q · filed 2019-11-01 | $2.60M derived: sum of 2 quarters · filed 2019-11-01 | $3.80M 10-Q · filed 2019-11-01 | |
| 2018-06-30 | $1.30M 10-Q · filed 2019-08-09 | $2.50M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.20M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |